世界卫生组织风险饮酒水平降低可作为酒精临床试验的主要疗效终点
本文综述34篇文献,评估世界卫生组织风险饮酒水平(WHO RDL)降低作为酒精使用障碍(AUD)治疗终点的有效性。流行病学、社区样本和临床试验结果表明,饮酒减少与患者感受和功能改善相关,包括物质使用障碍及躯体和精神疾病风险降低、酒精相关后果减少、渴求降低和医疗费用下降。FDA近期将WHO RDL至少降低2级定义为酒精药物疗法试验的主要终点,可能促进AUD药物开发并推动危害减少范式转变。
要点
- WHO RDL降低至少2级已被FDA认定为酒精药物疗法试验的主要终点。
- 饮酒减少与患者感受和功能改善、酒精相关后果及医疗费用降低相关。
- WHO RDL终点可能促进AUD药物开发并推动危害减少治疗范式。
核心结论
- WHO风险饮酒水平降低可作为酒精临床试验的主要疗效终点,并可能推动AUD治疗的危害减少范式转变。
研究设计与样本
- 本文为叙述性综述,共纳入34篇评估WHO风险饮酒水平作为AUD患者感受和功能替代标志物的文章。
主要发现
- 流行病学研究、社区样本和临床试验结果表明,饮酒减少与物质使用障碍及躯体和精神疾病风险降低相关。
- 饮酒减少还与酒精相关后果减少、渴求降低和医疗费用下降相关。
- 饮酒减少与功能和生活质量改善相关。
- 大多数临床试验参与者实现了饮酒减少,且活性药物 vs 安慰剂在WHO RDL降低上的效应量与替代终点相似或更优。
关键数值与推荐
- FDA近期将WHO风险饮酒水平至少降低2级认定为酒精药物疗法试验的主要终点。
临床怎么用
- WHO RDL可能特别适用于临床实践中针对性的饮酒减少目标。
- FDA对WHO RDL终点的认可可能鼓励患者寻求以饮酒减少为目标的治疗。
- 临床医生可据此处方已被证明有效支持饮酒减少的药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alcohol use disorder (AUD) is a highly prevalent and costly psychiatric disorder. Abstinence has been considered the optimal outcome of treatment for AUD. Yet, most individuals with AUD do not seek treatment because they do not have a goal of abstinence. The Food and Drug Administration (FDA) has recently qualified reductions in drinking, defined by at least a 2-level reduction in the World Health Organization risk drinking levels (WHO RDLs), as a primary end point for alcohol pharmacotherapy trials. The approval of drinking reductions as an end point for alcohol clinical trials aligns with an accumulating literature on drinking reductions in the alcohol field. This article provides a narrative review of 34 articles that have examined WHO RDLs as a surrogate marker of how people with AUD feel and function. OBSERVATIONS: Results from epidemiological studies, community samples, and clinical trials indicate that drinking reductions are associated with improvements in how patients feel and function, including reduced risk of substance use disorder and medical and psychiatric diseases and reductions in alcohol-related consequences, craving, and health care costs. Drinking reductions are also associated with improvements in functioning and quality of life. Drinking reductions are also achieved by most clinical trial participants, and effect sizes for the WHO RDL reductions for active medications vs placebo are similar to or better than alternative end points. CONCLUSIONS AND RELEVANCE: The FDA acceptance of reduction in WHO RDLs as a primary end point for alcohol clinical trials may increase opportunities for AUD medications development, encourage patients to seek treatments that target drinking reductions, and engage clinicians in prescribing medications shown to be effective in supporting drinking reductions. The WHO RDLs may be particularly useful for targeted drinking reductions in clinical practice. Qualification of the WHO RDL end point facilitates a paradigm shift toward a harm reduction approach in AUD treatment.
引用
- Witkiewitz K, Anton RF, O'Malley SS, et al. Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials: A Review. JAMA Psychiatry. 2025. PMID: 40960803. doi:10.1001/jamapsychiatry.2025.2508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。